Abstract

Aspects of the disclosure relate to compositions and methods for modulating RNA. The methods include methods for treating a haploinsufficiency disorder in a subject, the method comprising administering a polypeptide, delivery vehicle, or composition described herein. Also described are delivery vehicles comprising the polypeptides, nucleic acids, and/or expression vectors described herein.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12P 21/00 - Preparation of peptides or proteins
• C07K 19/00 - Hybrid peptides
• C12N 1/16 - YeastsCulture media therefor
• C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material

Abstract

Systems, methods, and computer program products for characterizing photons are described. A signal from a superconducting nanowire single photon detector (SNSPD) is transmitted to a converter configured, based on the signal, to output data at a sampling rate. The data from the converter is transmitted to a computing node configured to infer one or more attributes of the at least one photon from the data.

IPC Classes  ?

• G01J 1/44 - Electric circuits
• G01S 7/4861 - Circuits for detection, sampling, integration or read-out
• G06N 10/70 - Quantum error correction, detection or prevention, e.g. surface codes or magic state distillation
• G06N 21/64 -

Abstract

This disclosure relates to compositions and methods for treating lung disorders, including, for example, pulmonary fibrosis, and other fibrotic disorders. Thioredoxin domain-containing 5 (TXNDC5) is significantly increased in fibrotic lungs from human PF patients. Therefore, a targeted nanoparticle comprising an inhibitor of TXNDC5 was developed, which may have potential to treat pulmonary fibrosis.

IPC Classes  ?

• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61P 11/00 - Drugs for disorders of the respiratory system
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

Stable, high-capacity tin electrodes, electrochemical cells that incorporate the tin electrodes as anodes, methods for operating the electrochemical cells, and methods of making the tin electrodes are provided. The tin electrodes are formed by electroplating tin in an aqueous acidic electrolyte solution containing tin ions and quaternary onium cations. The quaternary onium ions promote selective three-dimensional growth of Sn (211) crystal grains to form a dense, homogeneous polycrystalline tin layer.

IPC Classes  ?

• B01J 23/14 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of germanium, tin or lead
• B01J 35/33 - Electric or magnetic properties
• C25D 3/30 - ElectroplatingBaths therefor from solutions of tin
• H01L 21/02 - Manufacture or treatment of semiconductor devices or of parts thereof
• B32B 15/04 - Layered products essentially comprising metal comprising metal as the main or only constituent of a layer, next to another layer of a specific substance
• C25D 7/00 - Electroplating characterised by the article coated

Abstract

The present inventive concept relates to methods of nucleic acid sequencing, and applications and uses of the same. Aspects of the inventive concept include nanopore sequencing on nucleic acids, such as ribonucleic acids (RNAs), including, but not limited to, transfer RNAs (tRNAs). Further aspects include kits for performing the methods, and applications of the methods of the inventive concept as substantively described herein.

IPC Classes  ?

• C12Q 1/6869 - Methods for sequencing

Abstract

Aspects of the present disclosure are directed to methods, compositions, and kits for detection and analysis of DNA and RNA cytosine methylation and/or RNA pseudouridylation. Certain aspects include methods, compositions and kits useful in bisulfite sequencing of methylated and/or pseudouridinylated nucleic acids, including methylated and/or pseudouridinylated nucleic acids from low-input samples such as cell-free DNA (cfDNA) and cell-free RNA, long fragment polynucleotides, and/or cfDNA and DNA from formalin-fixed paraffin-embedded (FFPE) samples. Also disclosed herein are methods, compositions and kits useful in bisulfite sequencing of methylated and/or pseudouridinylated nucleic acids with low nucleic acid damage, higher true positive results, and/or lower false negative results.

IPC Classes  ?

• C01D 5/00 - Sulfates or sulfites of sodium, potassium, or alkali metals in general
• C12Q 1/6827 - Hybridisation assays for detection of mutation or polymorphism
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Abstract

This disclosure relates to methods for modulating activity of cells and tissue with materials that are capable of being activated by light, such methods useful for treating diseases. The disclosure also provides devices and systems suitable for use in such methods, particularly devices and systems having oxygen plasma-treated p-type (boron) silicon.

IPC Classes  ?

• A61N 5/06 - Radiation therapy using light

Abstract

A system for individually controlling a plurality of qubits in an atom array includes a plurality of optical modulators and a fiber array having a plurality of optical fibers. Each of the optical fibers has an fiber input coupled to a modulator output of a respective one of the optical modulators. The system also includes a lens configured to image the output of the fiber array onto the qubits such that an fiber output of each of the optical fibers is imaged onto a respective one of the qubits. The lens may be a microscope objective. The system may also include a splitter that splits a single laser beam into a plurality of modulator-input beams such that each of the modulator-input beams is coupled to a respective one of the optical modulators. Each optical modulator may include an acousto-optic modulator, electro-optic modulator, mechanical shutter, or other optical component.

IPC Classes  ?

• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control
• G02F 1/33 - Acousto-optical deflection devices

Abstract

Provided herein are compositions, methods, and kits suitable for detection and/or quantification of calprotectin in a sample (including extracts thereof). In some aspects, compositions, methods, and/or kits comprise a Fab-Enabled Split Luciferase Calprotectin Assay (FESCA) or components thereof, a novel quantitative method for calprotectin measurement. In some aspects, provided herein are two new fragment antigen binding proteins (Fabs), CP16 and CP17, which bind to different epitopes of the calprotectin complex. These Fabs can be fused, directly or indirectly, with a reporter system, such as split NanoLuciferase fragments, enabling the reconstitution of active luciferase upon binding to calprotectin either in solution or in varied immobilized assay formats. Technologies provided herein can be utilized to detect physiologically relevant calprotectin levels across various sample types, including serum, plasma, whole blood, and stool extracts, and can be utilized in methods of treating a subject.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

A lithium oxygen electrochemical cell includes an anode that includes lithium metal, a porous oxygen cathode that includes a conductive carbon and aluminum, and an electrolyte.

IPC Classes  ?

• C25B 1/14 - Alkali metal compounds
• C25B 11/032 - Gas diffusion electrodes
• C25B 11/046 - Alloys
• C25B 11/065 - Carbon
• C25B 11/089 - Alloys
• C25B 15/08 - Supplying or removing reactants or electrolytesRegeneration of electrolytes

Abstract

Methods, assays, and compositions for identifying molecular subtypes of metastatic cancer are disclosed. The disclosed methods include determining expression levels of genes in a sample of metastatic tissue and identifying the molecular subtype of the metastasis based on the determined expression levels using a neural network-based classifier. Methods may further include providing a prognosis and making a treatment decision based on the molecular subtype of the metastasis. Further disclosed are methods of treatment of a cancer subject with a particular cancer therapy (e.g., local therapy, immunotherapy, EGFR inhibitor therapy) based on a molecular subtype of a metastasis from the subject.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G16B 40/00 - ICT specially adapted for biostatisticsICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

Aspects herein include methods, kits, and systems for evaluating a subject comprising detecting genetic mutation(s) in the DNA sequence of one or more oral cavity squamous cell carcinoma (OCSCC) biomarker(s) in a biological sample from the subject comprising DNA, wherein the OCSCC biomarker(s) comprise TP53, CDKN2A, FAT1, CASP8, NOTCH1, PIK3CA, and/or HRAS along with detecting or determining an HPV infection.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

This disclosure relates to methods for treatment of prostate cancer.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/4166 - 1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
• A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
• A61K 31/569 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone substituted in position 17 alpha, e.g. ethisterone
• A61P 35/00 - Antineoplastic agents

Abstract

in situin situ in the second network to form a double network hydrogel. A method of manufacturing the mixed ion/electron conducting material and an implantable medical device including the mixed ion/electron conducting material are also described.

IPC Classes  ?

• A61L 27/34 - Macromolecular materials
• A61L 31/10 - Macromolecular materials
• A61L 29/08 - Materials for coatings
• A61L 26/00 - Chemical aspects of, or use of materials for, liquid bandages
• A61L 31/14 - Materials characterised by their function or physical properties
• C08J 3/00 - Processes of treating or compounding macromolecular substances

Abstract

Aspects herein include methods, kits, and systems for evaluating a subject comprising detecting genetic mutation(s) in the DNA sequence of one or more oral cavity squamous cell carcinoma (OCSCC) biomarker(s) in a biological sample from the subject comprising DNA, wherein the OCSCC biomarker(s) comprise TP53, CDKN2A, FAT1, CASP8, NOTCH1, PIK3CA, and/or HRAS along with detecting or determining an HPV infection.

IPC Classes  ?

• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The current disclosure describes compositions and methods that may be administered to prevent immune responses against therapeutic molecules. The disclosure provides for a composition comprising a polypeptide comprising an engineered Fms Related Receptor Tyrosine Kinase 3 Ligand (Flt3L) protein. Also described is a method of treatment comprising: administering to a subject in need thereof, an effective amount of an engineered Flt3L protein of the disclosure. Methods also relate to a method for inducing immunotolerance in a subject in need thereof comprising, the method comprising administering to the subject an engineered Flt3L protein of the disclosure.

IPC Classes  ?

• C07K 14/475 - Growth factorsGrowth regulators
• A61K 38/18 - Growth factorsGrowth regulators
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 37/04 - Immunostimulants
• C07K 14/765 - Serum albumin, e.g. HSA

Abstract

A method and devices for fabricating optical emitters. The method includes disposing a flake of a multi-layer material onto a wafer. The wafer has an aperture over which a portion of the flake is disposed. The flake has a first surface partially in contact with the wafer, and a second surface opposite the first surface. The method further includes disposing a deceleration mask layer adjacent the flake. The deceleration mask layer has a flake-side surface adjacent to the flake, and an exposed surface opposite the flake-side surface. An ion beam is directed at the exposed surface of the deceleration mask layer to decelerate ions of the ion beam until at least a portion of the ions are implanted in the flake.

IPC Classes  ?

• G01J 1/58 - Photometry, e.g. photographic exposure meter using luminescence generated by light
• C23C 14/04 - Coating on selected surface areas, e.g. using masks
• C23C 14/06 - Coating by vacuum evaporation, by sputtering or by ion implantation of the coating forming material characterised by the coating material
• C23C 14/48 - Ion implantation
• G01J 1/04 - Optical or mechanical part
• G01J 1/44 - Electric circuits
• G01J 3/02 - SpectrometrySpectrophotometryMonochromatorsMeasuring colours Details
• G01J 3/44 - Raman spectrometryScattering spectrometry

Goods & Services

Downloadable printable educational materials in the field of quantum technology; Downloadable reports featuring quantum technology policies, laws, and regulations Printed educational materials in the field of quantum technology; Printed reports featuring quantum technology policies, laws, and regulations Promoting technical and scientific investigation, research and experimentation in the field of scientific discovery through support of educational institutions and scientific organizations; Promoting public interest and awareness of quantum technology and the laws, policies and regulations relating to the quantum economy; Promoting the exchange of information and resources within the quantum and legal communities to achieve advances in the field of quantum technology Development and dissemination of printed educational materials of others in the field of quantum technology; Educational services, namely, conducting seminars, conferences, and panel discussions in the field of quantum technology policies, laws, and regulations and distribution of educational materials in connection therewith; Providing a website featuring resources, namely, non-downloadable publications in the nature of reports in the field of quantum technology and law; Education services, namely, providing panel discussions in the field of quantum technology policies, laws, and regulations; Organizing events in the field of quantum technology for cultural or educational purposes; Development and dissemination of printed educational materials of others in the field of quantum technology and law; Providing educational information in the academic field of quantum technology and law for the purpose of academic study; Developing educational resources for others in the field of quantum technology and law; Providing on-line resource guides for business, universities, corporations, investors, and policymakers in the fields of law and quantum technology

Abstract

A method for pre-forming cathode electrolyte interphase on electroactive material, the method comprising sourcing a current or voltage to an electrochemical reactor comprising a cation source, an electrolyte mixture, one or more additives, and a cathode active material in contact with one another, wherein the current or voltage serves to ionize and form cations at the cation source that reacts with the cathode active material to pre-form cathode electrolyte interphase on the cathode active material.

IPC Classes  ?

• H01M 4/04 - Processes of manufacture in general
• H01M 4/02 - Electrodes composed of, or comprising, active material
• H01M 4/505 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of manganese of mixed oxides or hydroxides containing manganese for inserting or intercalating light metals, e.g. LiMn2O4 or LiMn2OxFy

Abstract

A method for adjusting the transition metal composition of a lithium transition metal oxide cathode active material, such as a lithium nickel manganese cobalt oxide material, comprises precipitating a transition metal hydroxide onto the surface of particles of a first lithium transition metal oxide to form coated particles; isolating the coated particles; combining the isolated coated particles with an amount of lithium hydroxide; and calcining the resulting mixture at a temperature in the range of about 700 to about 950° C. (e.g., 800 to 900° C.) to form a second lithium transition metal oxide that has a different transition metal composition than the first lithium transition metal oxide material; wherein the amount of lithium hydroxide is selected to afford a target ratio of lithium to transition metals in the second lithium transition metal oxide after calcining.

IPC Classes  ?

• H01M 10/54 - Reclaiming serviceable parts of waste accumulators
• C01G 53/00 - Compounds of nickel

Abstract

A microwave-optical transducer device, comprising: an optical cavity formed by a first dielectric substrate having a first optical reflector disposed thereon and a second dielectric substrate having a second optical reflector disposed thereon; a spin ensemble material disposed in the optical cavity, the spin ensemble material disposed on the second dielectric substrate; a planar microwave resonator disposed proximal to the spin ensemble material and inductively coupled thereto; and wherein: the optical cavity is configured to expose the spin ensemble material to an optical-range electromagnetic field; the microwave resonator is configured to expose the spin ensemble material to a micro wave-range electromagnetic field; the spin ensemble material, when exposed to a magnetic field and to an optical pump field having a driving frequency Ωp, to emit the optical-range electromagnetic field upon exposure to the microwave electromagnetic field, and to emit the microwave electromagnetic field upon exposure to the optical-range electromagnetic field.

IPC Classes  ?

• G02F 1/00 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics
• H01P 7/06 - Cavity resonators
• H01P 7/10 - Dielectric resonators

Abstract

A system for electrically detecting a biomarker, the system comprising: a sample unit comprising: a sample chamber configured to contain a fluid sample; a reference electrode in fluid communication with the sample chamber; a detection zone in fluid communication with the sample chamber and configured to capture a biomarker; a signal zone in fluid communication with the detection zone; and a working electrode configured such that its surface potential changes in the presence of charged species (e.g., protons) generated by a reaction (e.g., between an enzyme and a radical substrate) occurring in the signal zone; and a measuring unit comprising a field-effect transistor in electrical communication with the reference electrode and the working electrode, the measuring unit configured to measure a change in surface potential of the working electrode due to generated charged species.

IPC Classes  ?

• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 1/38 - Diluting, dispersing or mixing samples
• G01N 27/414 - Ion-sensitive or chemical field-effect transistors, i.e. ISFETS or CHEMFETS
• G01N 27/02 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating impedance
• H10D 30/60 - Insulated-gate field-effect transistors [IGFET]

Abstract

A solid-state electrolyte material includes doped lithium argyrodite of formula of Li6-2a-bMaTCh5-a-bOaX1+b; where 0

IPC Classes  ?

• H01M 10/0562 - Solid materials
• C01B 25/16 - Oxyacids of phosphorusSalts thereof
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
• H01M 10/0585 - Construction or manufacture of accumulators having only flat construction elements, i.e. flat positive electrodes, flat negative electrodes and flat separators

Abstract

Aspects herein concern cdtR mutations that can lead to reduced or absent virulence in C. difficile bacteria. Disclosed are compositions and methods using the cdtR mutants to treat or prevent C. difficile infections or diseases caused by C. difficile. Also disclosed are methods for detecting or determining C. difficile virulence based on mutation status of the cdtR gene in C. difficile.

IPC Classes  ?

• A61K 35/74 - Bacteria
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/02 - Bacterial antigens
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 31/04 - Antibacterial agents
• C12N 1/20 - BacteriaCulture media therefor
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
• C12R 1/01 - Bacteria or actinomycetales

Abstract

Aspects of the present disclosure are directed to methods, compositions, and kits for detection and analysis of RNA modifications in cell-free RNA. The RNA modification can be used to generate an RNA modification signature in cell-free RNA from a patient.

IPC Classes  ?

• G06N 3/08 - Learning methods
• C12Q 1/6869 - Methods for sequencing
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria

Abstract

Provided are compositions and methods for determining the presence and/or the location of 5-hydroxymethylcytosine (5hmC) in DNA samples. The method involves contacting an isolated DNA sample sequentially with a T4 alpha-glucosyltransferase (a-GT) and subsequently with a Brig1 protein that introduces abasic sites at the location of 5hmCs. Isolated and modified Brig1 proteins are provided. Kits that contain the Brig1 protein are also provided.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• C12Q 1/686 - Polymerase chain reaction [PCR]

Abstract

Blocking antibodies against αMβ2 (CBP-α-αMβ2), αM (CBP-α-αM), α3 (CBP-α-α3), and anti-TGFβ as well as inhibitors of Talin2 reverse fibrosis in a mouse fibrosis model. Accordingly, aspects of the disclosure relate to inhibitors of Talin2 and inhibitors of the integrins αMβ2, αM, and α3. Aspects relate to a method for treating and/or reversing fibrosis in a subject comprising administering a composition comprising an inhibitor of Talin2 or a composition comprising a nucleic acid of the disclosure. Further aspects relate to a method for treating and/or reversing fibrosis in a subject comprising administering a composition comprising an antibody conjugate of the disclosure or a composition comprising an inhibitor or blocking agent of integrin α3, αM, αMβ2, or combinations thereof to the subject. Methods also include treating kidney fibrosis in a subject comprising administering a composition comprising an anti-TGFβ antibody operatively linked to an ECM-affinity peptide. The methods may be for reducing or decreasing the amount of existing fibrosis. The methods differ from traditional methods for treating fibrosis, since the current methods do not delay or inhibit the progression of fibrosis, but instead have shown to reverse, reduce, and/or decrease existing fibrosis. Accordingly, methods of the disclosure may be used in a manner that provides treatment to existing fibrosis rather than a prophylactic to prevent more fibrosis.

IPC Classes  ?

• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61P 11/00 - Drugs for disorders of the respiratory system
• C07K 14/78 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
• C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

A method for designing proteins using multi-objective reinforcement learning can include generating, by one or more processors using a machine model, based on an initial protein sequence data structure, a plurality of protein sequences, the machine learning model configured based on reinforcement learning from a plurality of reward metrics including at least one reward metric associated with experimental data regarding example sequence data, scoring, by the one or more processors, using a plurality of scoring functions, the plurality of protein sequences, to select a subset of protein sequences of the plurality of protein sequences, and outputting one or more selected protein sequences of the subset of selected protein sequences.

IPC Classes  ?

• G16B 15/20 - Protein or domain folding
• G06N 20/00 - Machine learning
• G16B 40/20 - Supervised data analysis

Abstract

Tetrathiafulvalene-2,3,6,7-tetrathiolate (TTFtt) bridged bimetallic complexes with radical character which are bright, air- and water-stable, persistent and exhibit excellent near-infrared photophysical properties; and methods of use of the TTFtt complexes for imaging, guidance of surgery, as qubits, and for interventional medical treatments as theranostic agents are described.

IPC Classes  ?

• A61K 49/00 - Preparations for testing in vivo

Abstract

Provided herein are compositions and methods for treating hemoglobinopathies involving inhibiting activity or expression of TET2. Inhibiting the activity or expression of TET2 may comprise providing to the subject EPAG and optionally one or more additional inhibitors of TET2. Inhibiting the activity of TET2 may comprise mutating a residue within the catalytic core of TET2 in the subject.

IPC Classes  ?

• A61K 31/4152 - 1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
• A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 7/06 - Antianaemics
• C07D 231/46 - Oxygen atom in position 3 or 5 and nitrogen atom in position 4
• C07D 487/04 - Ortho-condensed systems

Abstract

CACNA1ACACNA1ACACNA1ACACNA1A gene, respectively, including those that lead to haploinsufficiencies. Alleviating such issues can be useful to treat neurological disorders that result from such mutations.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61P 25/00 - Drugs for disorders of the nervous system
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression

Abstract

Implantable bioelectronic semiconducting polymers including thiophene and/or selenophene are provided. Films including the polymers coated on substrates are further provided. Organic electrochemical transistors including channels including the polymers are further provided. Methods of preparing the polymers are further provided. Bioelectronic implant comprising polymers coated on substrates are further provided.

IPC Classes  ?

• H01B 1/12 - Conductors or conductive bodies characterised by the conductive materialsSelection of materials as conductors mainly consisting of other non-metallic substances organic substances
• C08G 61/12 - Macromolecular compounds containing atoms other than carbon in the main chain of the macromolecule

Abstract

At least one aspect of the present disclosure relates to a two-dimensional mineral membrane including a first phyllosilicate material and a second phyllosilicate material crosslinked with the first phyllosilicate material, where a surface of at least one of the first phyllosilicate material or the second phyllosilicate material includes at least one functional group. Another aspect of the present disclosure relates to a method of producing a two-dimensional mineral membrane. The method includes providing a first phyllosilicate material and a second phyllosilicate material, exfoliating a mixture of the first phyllosilicate material and the second phyllosilicate material into a plurality of flakes, crosslinking the first phyllosilicate material with the second phyllosilicate material, functionalizing a surface of at least one of the first phyllosilicate material or the second phyllosilicate material, and restacking the plurality of flakes to form a membrane.

IPC Classes  ?

• B01D 71/02 - Inorganic material
• B01D 67/00 - Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
• B01D 69/12 - Composite membranesUltra-thin membranes

Abstract

Provided herein are porous, thin substrates (e.g., holey grids) comprising lipid bilayers formed across and/or within holes in the substrates, methods of forming bilayers within the holes of porous, thin substrates (e.g., holey grids), and methods of conducting structural analysis (e.g., by cryoEM) of membrane proteins, membrane-embedded particles, or membrane-attached particles within the lipid bilayers.

IPC Classes  ?

• G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups
• B82Y 15/00 - Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
• G01N 23/2251 - Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups , or by measuring secondary emission from the material using electron or ion microprobes using incident electron beams, e.g. scanning electron microscopy [SEM]

Abstract

A method of surfacing high-surprisal information includes reading an input document. The input document can comprise an ordered sequence of tokens. The method includes, for each token of the ordered sequence of tokens, generating by a language model a probability distribution of predicted tokens based on preceding tokens in the ordered sequence. The method includes comparing each token to its predicted tokens to determine a probability of occurrence of that token. The method includes, based on the probability of occurrence of each token, assigning a surprise value thereto.

IPC Classes  ?

• G06F 40/284 - Lexical analysis, e.g. tokenisation or collocates
• G06F 40/40 - Processing or translation of natural language
• G06N 3/0455 - Auto-encoder networksEncoder-decoder networks
• G06N 3/047 - Probabilistic or stochastic networks

Abstract

Provided herein are DNA methylation arrays displaying oligonucleotides containing human CpG sites that are differentially methylated in subjects suffering from asthma and/or allergies relative to the general population, and methods of use thereof.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

An optical cavity array includes a plurality of mirrors that form an optical cavity, a first lens system located within the optical cavity, and a second lens system located within the optical cavity. The first lens system has a first output facing a first mirror of the plurality of mirrors and a second output facing a second mirror of the plurality of mirrors. The second lens system has a second input facing the first input and a second output facing the second mirror. The first and second lens systems are configured such that the optical cavity supports longitudinal modes that are transversely non-degenerate, forming spatially separated waists that lie along a focal plane that is axially located between the first and second inputs. When the longitudinal modes are excited, the waists may be used as an array of optical dipole traps.

IPC Classes  ?

• G02B 17/00 - Systems with reflecting surfaces, with or without refracting elements
• G21K 1/00 - Arrangements for handling particles or ionising radiation, e.g. focusing or moderating

Abstract

The disclosure provides for methods and compositions that can be used for modulating an immune response. Described are methods comprising administering an effective amount of (a) an adjuvant; and (b) one or more of bafetinib (INNO-406), LY3009120, MK-8353 (SCH900353), amodiaquine, zanubrutinib (BOB-3111), Ku55933, Tucidinostat, PD318088, WNK463, and TRx0237 (LMTX) mesylate to a subject. The methods may he for the vaccination of subjects, or for the treatment or prevention of cancer, graft rejection, graft versus host disease, a bacterial infection, or a viral infection in a subject. The method may be for modulating an immune response in vivo, in vitro, or ex vivo. The methods also include immune activation of a population of immune cells in vitro or ex vivo. Also described is a method for identifying the efficacy of an adjuvant.

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
• A61K 31/4406 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/4706 - 4-Aminoquinolines8-Aminoquinolines, e.g. chloroquine, primaquine
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61P 31/14 - Antivirals for RNA viruses
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

A semiconductor device may include a channel layer including a two-dimensional material layer and a molecular crystal layer on the two-dimensional material layer, the two-dimensional material layer including a two-dimensional semiconductor material; a source electrode and a drain electrode, which respectively may be on both sides of the channel layer; and a gate insulating layer and a gate electrode, which respectively may be on the channel layer between the source electrode and the drain electrode. The molecular crystal layer may include a plate-shaped aromatic compound of C20-C40, and may have a thickness of 1 molecular layer to 5 molecular layers.

IPC Classes  ?

• H10D 30/47 - FETs having zero-dimensional [0D], one-dimensional [1D] or two-dimensional [2D] charge carrier gas channels having 2D charge carrier gas channels, e.g. nanoribbon FETs or high electron mobility transistors [HEMT]
• H10D 30/01 - Manufacture or treatment
• H10D 62/40 - Crystalline structures
• H10D 62/80 - Semiconductor bodies, or regions thereof, of devices having potential barriers characterised by the materials

Abstract

Spectrally selective textiles for radiative cooling are provided. Also provided are methods for making the textiles. The spectrally selective textiles have an asymmetrical design characterized by a high and selective outward-facing emissivity and a broadband inward-facing emissivity that efficiently emits heat from a wearer of the textile to the outer environment, while suppressing the radiative heat gain. The textiles have multiple layers having different cooling functions, including: a fabric having broadband emission for thermal radiation; a layer of nanostructures overlying the fabric layer; and a layer of non-woven polymer fibers overlying the nanostructures.

IPC Classes  ?

• A41D 31/32 - Retroreflective
• D01F 1/10 - Other agents for modifying properties
• B32B 15/085 - Layered products essentially comprising metal comprising metal as the main or only constituent of a layer, next to another layer of a specific substance of synthetic resin comprising polyolefins
• D01D 5/00 - Formation of filaments, threads, or the like

Abstract

A catalytic composition and process for forming and utilizing same in alkane dehydrogenation. An organometallic active material is deposited onto a silicon derived support such as a silicon imidonitride or silicon oxynitride. The active material facilitates the heterolytic C—H bond cleavage across a metal oxide bond.

IPC Classes  ?

• B01J 31/16 - Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
• B01J 27/24 - Nitrogen compounds

Abstract

A photonic chip includes a substrate and several nanophotonic devices extending laterally away from an edge of the substrate. Each nanophotonic device is free-standing where it extends laterally past the edge of the substrate, with each neighboring pair of nanophotonic devices forming a gap therebetween. Atoms trapped in optical tweezers may be transported into the gap and close enough to a nanophotonic device that the atoms strongly couple to the nanophotonic device. Each nanophotonic device may include a waveguide, resonator, coupler, or a combination thereof. To excite modes of a nanophotonic device, a free-space optical beam may be coupled into a distal end of the nanophotonic device. A top face of each nanophotonic device may be reflective to create an optical lattice over the top face. An atom may then be trapped in the potential minimum of the optical lattice that is closest to the top face.

IPC Classes  ?

• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control
• G02B 6/43 - Arrangements comprising a plurality of opto-electronic elements and associated optical interconnections
• G06N 10/20 - Models of quantum computing, e.g. quantum circuits or universal quantum computers
• B82Y 20/00 - Nanooptics, e.g. quantum optics or photonic crystals
• G02B 6/10 - Light guidesStructural details of arrangements comprising light guides and other optical elements, e.g. couplings of the optical waveguide type
• G21K 1/00 - Arrangements for handling particles or ionising radiation, e.g. focusing or moderating

Abstract

An apparatus suitable for defect monitoring of continuous coating processes is described herein. The apparatus comprises a first beam splitter; an objective lens assembly; a scanning mirror interposed between the first beam splitter and the objective lens assembly; a dichroic filter that is positioned between the first beam splitter and the scanning mirror; and a second beam splitter. In use, a laser emits light toward the first beam splitter. The light passes through the first beam splitter and the dichroic filter to the scanning mirror and then through the objective lens assembly onto a Raman-active analyte in a coating. Raman scattering from the analyte passes through the objective lens assembly to the scanning mirror and then to the dichroic filter, directing the scattered light to the second beam splitter and then to the detector to quantitatively detect the Raman-scattered light.

IPC Classes  ?

• G01N 21/65 - Raman scattering
• B05C 5/02 - Apparatus in which liquid or other fluent material is projected, poured or allowed to flow on to the surface of the work from an outlet device in contact, or almost in contact, with the work
• B05C 11/00 - Component parts, details or accessories not specifically provided for in groups
• G01B 11/06 - Measuring arrangements characterised by the use of optical techniques for measuring length, width, or thickness for measuring thickness
• G01N 21/89 - Investigating the presence of flaws, defects or contamination in moving material, e.g. paper, textiles

Abstract

The present disclosure relates to engineered RNA m6A demethylases with disrupted low complexity regions (LCRs) for expression in plants, as well as recombinant DNA encoding the engineered RNA m6A demethylases, vectors encoding the recombinant DNA, plants including the engineered RNA m6A demethylases, and method of improving the growth of plants using the engineered RNA m6A demethylases, including increased root growth and elevated photosynthesis. The present disclosure further relates to methods of improving growth of a plant, including increased root growth and elevated photosynthesis, by modifying endogenous ALKBH5 homolog genes to include disrupted LCRs, and plants produced by those methods.

IPC Classes  ?

• A61K 38/44 - Oxidoreductases (1)
• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
• C12N 15/53 - Oxidoreductases (1)

Abstract

The present disclosure relates to engineered RNA m6A demethylases with disrupted low complexity regions (LCRs) for expression in plants, as well as recombinant DNA encoding the engineered RNA m6A demethylases, vectors encoding the recombinant DNA, plants including the engineered RNA m6A demethylases, and method of improving the growth of plants using the engineered RNA m6A demethylases, including increased root growth and elevated photosynthesis. The present disclosure further relates to methods of improving growth of a plant, including increased root growth and elevated photosynthesis, by modifying endogenous ALKBH5 homolog genes to include disrupted LCRs, and plants produced by those methods.

IPC Classes  ?

• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C12Q 1/6895 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae

Abstract

Techniques disclosed herein for diagnosing faults include receiving a description of a sensor set. The techniques further include decomposing the sensor set, constructing a data-driven model for each sensor subset, and determining a fault association for each data-driven model residual. Using sensor measurements of a first sensor subset, the techniques further include calculating residuals of (i) the data-driven model and (ii) a physics-based model, determining a fault of a component or a sensor of the first sensor subset based on the residuals, and generating an alert indicating that the fault is present in the component or the sensor. These disclosed techniques advantageously integrate conventionally independent diagnostic techniques into a single diagnostic framework that outperforms such conventional configurations. Moreover, the disclosed techniques enable the integration of additional diagnostic techniques into well-established and/or otherwise currently implemented diagnostic approaches for a particular system, which was previously unachievable in conventional diagnostic systems.

IPC Classes  ?

• F15B 19/00 - Testing fluid-pressure actuator systems or apparatus, so far as not provided for elsewhere

Abstract

A method and system for diagnosing an idiopathic psychosis patient and improving treatment targeting for that patient. Cognitive performance is measured on the patient. Pro- and anti-saccade signals are measured on the patient. Motor inhibition is measured on the patient. EEG signals are measured on the patient. Principal components analysis is applied to the measured signals and scales to determine the most significant features. The patient is evaluating on at least 11 dimensions of neuro-cognitive performance. A trained numerical taxonomy approach is used to classify the patient as belonging to a B-SNP psychosis Biotype and the patient's condition is categorized based on the classified Biotype. The B-SNIP psychosis Biotype is used to implement targeted treatment for an individual patient. The diagnostic algorithm is continuously re-trained using new cases and new laboratory tests to improve precision of B-SNIP psychosis Biotypes diagnosis and the accuracy of selecting treatments for individual patients.

IPC Classes  ?

• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
• G16H 20/70 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mental therapies, e.g. psychological therapy or autogenous training
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

N6-methyladenosine (m6A) is the most abundant internal modification on mammalian messenger RNA (mRNA). It is installed by a writer complex and can be reversed by erasers such as the fat mass and obesity-associated protein FTO. Despite extensive research, the primary physiological substrates of FTO in mammalian tissues and development remain elusive. Aspects disclosed show that FTO mediates m6A demethylation of long-interspersed element-1 LINE1 RNA in mouse embryonic stem cells (mESCs), regulating LINE1 RNA abundance and the local chromatin state, which in turn modulates transcription of LINE1-containing genes. FTO-mediated LINE1 RNA m6A demethylation also plays regulatory roles in shaping chromatin state and gene expression during mouse oocyte and embryonic development. FTO overexpression is also disclosed to modulate fertility.

IPC Classes  ?

• A61D 19/02 - Instruments or methods for reproduction or fertilisation for artificial insemination
• A01K 29/00 - Other apparatus for animal husbandry
• A61D 19/04 - Instruments or methods for reproduction or fertilisation for embryo transplantation
• C12N 5/09 - Tumour cells
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/877 - Techniques for producing new mammalian cloned embryos
• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection

Abstract

An electrochemical reactor for capturing carbon dioxide and producing bicarbonate and hydrogen is described herein. The electrochemical reactor is useful for, among other things, converting biogas to a bicarbonate and hydrogen feedstock for biomethanation. The reactor comprises at least one reactor unit comprising an electrolyzer cell and at least one alkaline water electrolysis (AWE) cell adjacent to the electrolyzer cell. The electrolyzer cell comprises an anode spaced from a cathode by an ion exchange membrane between the anode and the cathode; and the electrolyzer cell is adapted and arranged to allow a flow of a neutral liquid electrolyte to contact the anode and the cathode. The ion exchange membrane can be a cation exchange membrane (CEM), or an anion exchange membrane (AEM). The AWE cell comprises a second anode spaced from a second cathode by a porous diaphragm.

IPC Classes  ?

• C25B 1/14 - Alkali metal compounds
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12P 5/02 - Preparation of hydrocarbons acyclic
• C25B 1/04 - Hydrogen or oxygen by electrolysis of water
• C25B 9/23 - Cells comprising dimensionally-stable non-movable electrodesAssemblies of constructional parts thereof with diaphragms comprising ion-exchange membranes in or on which electrode material is embedded
• C25B 9/77 - Assemblies comprising two or more cells of the filter-press type having diaphragms
• C25B 11/031 - Porous electrodes
• C25B 15/08 - Supplying or removing reactants or electrolytesRegeneration of electrolytes

Abstract

In aspects, the invention provides a method of detecting a nucleotide modification in a sample comprising RNA, the method comprising: reacting RNA in the sample with periodate to form periodate-treated RNA in the sample, sequencing periodate-treated RNA in the sample, and detecting a modification signature in the sequence.

IPC Classes  ?

• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
• C12Q 1/6869 - Methods for sequencing

Abstract

Methods for synthesizing ternary or higher-order group III-V nanocrystals from lower-order group III-V nanocrystals via ion-exchange in a molten inorganic salt containing a group III metal element are provided. In the methods, binary or higher-order group III-V nanocrystals are dispersed in an inorganic molten inorganic salt that contains a group III metal element having an oxidation state of less than III. In the molten inorganic salt, group III ions in the nanocrystals undergo ion-exchange with group III ions in the salt to increase the order of the group III-V nanocrystals.

IPC Classes  ?

• B82B 3/00 - Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
• C09K 11/08 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing inorganic luminescent materials
• B82B 1/00 - Nanostructures formed by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units

Abstract

The present disclosure describes various methods, systems, and storage medium for acquiring super-resolution images with modulation. An apparatus includes a periodic pattern and a detector. The periodic pattern is configured to move to modify an original image field before the original image field propagates onto the detector of an imaging system, the original image field originating from a subject and comprising information of the subject, and the detector is configured to detect the modified original image field to acquire a plurality of detected images. The apparatus also includes a memory storing instructions and a processor in communication with the memory. When the processor executes the instructions, the processor is configured to cause the apparatus to reconstruct a super-resolution image based on the plurality of detected images, wherein an imaging resolution of the super-resolution image is better than an intrinsic resolution of the detector.

IPC Classes  ?

• G06T 3/4076 - Scaling of whole images or parts thereof, e.g. expanding or contracting based on super-resolution, i.e. the output image resolution being higher than the sensor resolution using the original low-resolution images to iteratively correct the high-resolution images

Abstract

This disclosure relates to compositions and methods for treating cancer and viral infections.

IPC Classes  ?

• C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 35/00 - Antineoplastic agents

Abstract

Aspects of the disclosure relate to a Effector system comprising at least one of each: i) a RNA hairpin binding domain; ii) a RNA targeting molecule comprising a RNA targeting region and at least one hairpin structure, wherein the hairpin structure of the RNA targeting molecule specifically binds to i; and iii) a Effector domain.

IPC Classes  ?

• C12N 9/22 - Ribonucleases
• C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle

Abstract

The present disclosure relates to optoelectronic devices and methods for optical epicardial pacing and endoscopic delivery devices and methods for translational photostimulation.

IPC Classes  ?

• A61N 5/06 - Radiation therapy using light
• A61B 1/06 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopesIlluminating arrangements therefor with illuminating arrangements

Abstract

Methods of synthesizing nanocrystals are provided which comprise combining a metal molecular precursor comprising a transition metal element or a group III element, and a group V molecular precursor comprising a group V element, in a molten inorganic salt solvent comprising a molten inorganic salt and under conditions to form a metal-V compound in the form of nanocrystals. No organic solvent is required. Also provided are colloids comprising single-crystalline nanocrystals composed of a metal-V compound. This includes single-crystalline III-V nanocrystals that exhibit band edge photoluminescence upon illumination with light under room temperature.

IPC Classes  ?

• B82B 3/00 - Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
• C09K 11/08 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing inorganic luminescent materials
• B82B 1/00 - Nanostructures formed by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units

Abstract

Systems and methods are provided to allow a user's lip to be used as a high temporal spatial resolution input and output surface. A stimulator is applied to the lip that includes a plurality of electrodes. These electrodes (e.g., a first subset) can be used to provide high-resolution electrohaptic stimulation to the lip, allowing the lip to be used to provide outputs of a user interface. These electrodes (e.g., a second subset) can also be used via capacitive or other sensing methods to detect the location of contact of the user's lip by the user's tongue and/or opposite lip, allowing the lip to be used to provide inputs to a user interface. Such a lip-based user interface provides hands-and eyes-free bidirectional information flow between a user and electronic systems, and does so in a manner that minimally impedes speech or eating.

IPC Classes  ?

• A61F 4/00 - Methods or devices enabling patients or disabled persons to operate an apparatus or a device not forming part of the body
• G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer

Abstract

A material can include a MXene. The material can include a first metal adsorbed on the MXene. The material can include a second metal adsorbed on the MXene. The second metal can be different from the first metal.

IPC Classes  ?

• C25B 11/032 - Gas diffusion electrodes
• C25B 1/23 - Carbon monoxide or syngas
• C25B 9/23 - Cells comprising dimensionally-stable non-movable electrodesAssemblies of constructional parts thereof with diaphragms comprising ion-exchange membranes in or on which electrode material is embedded
• C25B 9/75 - Assemblies comprising two or more cells of the filter-press type having bipolar electrodes
• C25B 9/77 - Assemblies comprising two or more cells of the filter-press type having diaphragms
• C25B 11/081 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of a single catalytic element or catalytic compound the element being a noble metal
• C25B 15/08 - Supplying or removing reactants or electrolytesRegeneration of electrolytes

Abstract

An electrochemical cell includes a cathode of oxygen or a metal oxide; an anode comprising lithium metal; and an electrolyte including a lithium sulfonylimide salt, a terminally fluorinated glycol ether, and an ionic liquid.

IPC Classes  ?

• H01M 10/0569 - Liquid materials characterised by the solvents
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
• H01M 10/0568 - Liquid materials characterised by the solutes
• H01M 50/417 - Polyolefins
• H01M 50/446 - Composite material consisting of a mixture of organic and inorganic materials

Abstract

Systems and methods are provided for providing electro-haptic stimulation to the palmar side of the hand without encumbering the hand, permitting a wearer to interact with objects normally while also receiving electro-haptic stimuli. This is accomplished by taking advantage of the higher threshold of stimulation needed to excite dorsal nerves of the hand relative to the palmar nerves of the hand, applying stimulating electrodes to the dorsal side of the hand and providing stimulation therethrough that is sufficient to elicit stimulation (and thus perceived haptic stimuli) of nerves in the palmar skin of the hand without stimulating nerves of the dorsal skin of the hand. Multiple electrodes can be provided to each finger, allowing for electro-haptic stimulation to be delivered to multiple different locations of each finger. The polarity of the stimulation can be controlled to deliver stimuli proximal or distal to a particular electrode.

IPC Classes  ?

• G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer

Abstract

This invention discloses methods and compositions for the treatment of demyelinating disorders. Specifically, the invention relates to the use guanabenz or guanabenz derivative for treating demyelinating disorders.

IPC Classes  ?

• A61K 31/155 - Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (HN=C(OH)NH2), isothiourea (HN=C(SH)—NH2)
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/136 - Amines, e.g. amantadine having aromatic rings, e.g. methadone having the amino group directly attached to the aromatic ring, e.g. benzeneamine
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/225 - Polycarboxylic acids
• A61K 31/277 - NitrilesIsonitriles having a ring, e.g. verapamil
• A61K 31/4409 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
• A61K 38/03 - Peptides having up to 20 amino acids in an undefined or only partially defined sequenceDerivatives thereof
• A61K 38/21 - Interferons
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The invention provides a method for recycling electrodes, the method comprising inductively heating the electrodes for a time sufficient to delaminate active material from current collectors underlying the active material. The invented process utilizes high frequency induction heating, which is a form of noncontact heating generated by the application of an electromagnetic field. The invention also provides a system for separating active material from current collectors of electrodes, the system comprising a particle transport mechanism enclosed in a housing; a first entry port for inserting electrodes into the housing and a second entry port for removing electrode components from the housing; and an inductive energy applicator for heating primarily interfaces comprising surfaces of the active material and surfaces of the current collectors opposing those active material surfaces.

IPC Classes  ?

• H01M 10/54 - Reclaiming serviceable parts of waste accumulators
• B32B 43/00 - Operations specially adapted for layered products and not otherwise provided for, e.g. repairingApparatus therefor
• F27B 9/06 - Furnaces through which the charge is moved mechanically, e.g. of tunnel type Similar furnaces in which the charge moves by gravity heated without contact between combustion gases and chargeFurnaces through which the charge is moved mechanically, e.g. of tunnel type Similar furnaces in which the charge moves by gravity electrically heated
• F27B 9/24 - Furnaces through which the charge is moved mechanically, e.g. of tunnel type Similar furnaces in which the charge moves by gravity characterised by the path of the charge during treatmentFurnaces through which the charge is moved mechanically, e.g. of tunnel type Similar furnaces in which the charge moves by gravity characterised by the means by which the charge is moved during treatment the charge moving in a substantially straight path being carried by a conveyor
• F27B 9/30 - Details, accessories or equipment specially adapted for furnaces of these types

Abstract

A method includes receiving a first plurality of aligned genomic sequences of a virus from a database. The aligned genomic sequences have a first common background. The method includes calculating a Qnet for each genomic sequence of the first plurality of aligned genomic sequences. The Qnet for each sequence is calculated by calculating a conditional inference tree for each index of the aligned genomic sequences using other indices in the aligned genomic sequences as predictive features, and calculating predictors for indices that were used as predictive features when calculating the conditional inference tree for each index.

IPC Classes  ?

• G16B 30/10 - Sequence alignmentHomology search

Abstract

A method includes providing a feedstock. The feedstock includes a first active material disposed on a first current collector and a second active material disposed on a second current collector. The method includes heating, by induction, the feedstock above a first temperature for a first period of time. The method includes delaminating the first active material from the first current collector during the first period of time. The method includes heating, by induction, the feedstock above a second temperature, which is greater than the first temperature, for a second period of time subsequent to the first period of time. The method includes delaminating the second active material from the second current collector during the second period of time.

IPC Classes  ?

• B32B 43/00 - Operations specially adapted for layered products and not otherwise provided for, e.g. repairingApparatus therefor
• H01M 10/54 - Reclaiming serviceable parts of waste accumulators

Abstract

Disclosed are approaches to non-invasively characterize a tumor or other lesion in a region of interest (ROI) based on various analyses of magnetic resonance imaging (MRI) data. The MRI data may correspond to ultrafast dynamic contrast enhanced MRI (DCE-MRI) and high spatial resolution DCE-MRI scans, and diffusion-weighted MRI (DW-MRI) scans of the ROI. Vasculature metrics may be determined, and tumor-associated blood flow velocity and/or tumor interstitial pressure may be obtained using the vasculature metrics as inputs to a computational fluid dynamics model. A combination of morphological vascular metrics and functional vascular metrics may be used to characterize the tumor. Malignancy, aggressiveness, treatment response, and other features of tumors or other lesions, in the breast or other regions of a patient, may be characterized through disclosed analyses of MRI data.

IPC Classes  ?

• G06T 7/00 - Image analysis
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• G06T 3/40 - Scaling of whole images or parts thereof, e.g. expanding or contracting
• G06T 7/11 - Region-based segmentation
• G06T 7/136 - SegmentationEdge detection involving thresholding
• G06T 7/155 - SegmentationEdge detection involving morphological operators
• G06T 7/20 - Analysis of motion

Abstract

This disclosure relates to compositions and methods for treating diabetes, including, for example, Type 1 diabetes (TID).

IPC Classes  ?

• A61K 9/1273 - PolymersomesLiposomes with polymerisable or polymerised bilayer-forming substances
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• C07K 14/605 - Glucagons

Abstract

An embodiment may involve determining a network traffic rate for a link; determining an amount of available memory for classification in a computing system operationally coupled to the link; selecting a classifier from a plurality of classifiers, wherein the classifiers are respectively associated with a time usage and a memory usage, wherein the classifiers were trained to predict network traffic types based on network traffic flows, and wherein the selection is based on: the network traffic rate, an amount of available memory, and the time usage and the memory usage of the classifier; and deploying the classifier to receive incoming network traffic flows by way of the link.

IPC Classes  ?

• H04L 47/2441 - Traffic characterised by specific attributes, e.g. priority or QoS relying on flow classification, e.g. using integrated services [IntServ]
• H04L 41/16 - Arrangements for maintenance, administration or management of data switching networks, e.g. of packet switching networks using machine learning or artificial intelligence

Abstract

This disclosure relates to methods for modulating activity of a cell capable of being activated by light and treating diseases with such methods. The disclosure also provides systems suitable for use in such methods, particularly systems having silicon nanostructures.

IPC Classes  ?

• A61N 5/06 - Radiation therapy using light
• A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• C12N 5/0793 - Neurons
• C12N 13/00 - Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves

Abstract

A method for classifying a mass in a medical image includes segmenting the medical image into a mass image and a background image, separating the mass image into a first mass component and a second mass component, extracting a set of radiomic-feature values from the first mass component and the second mass component, and processing the set of radiomic-feature values to classify the mass as malignant or benign. The mass image may be separated by clustering the pixels forming the mass image (e.g., using fuzzy c-means clustering). The method also includes outputting an indication that the mass is malignant or benign. The indication may be used to screen for, diagnose, treat, or monitor cancer in a human patient from which the medical image was obtained. The method may be implemented for use with ultrasound images, x-ray images, CT-scan images, PET-scan images, and MRI images.

IPC Classes  ?

• G06F 18/40 - Software arrangements specially adapted for pattern recognition, e.g. user interfaces or toolboxes therefor
• G06T 7/11 - Region-based segmentation
• G06T 7/12 - Edge-based segmentation
• G06T 15/08 - Volume rendering
• G06T 15/20 - Perspective computation
• G06T 17/00 - 3D modelling for computer graphics
• G06T 19/20 - Editing of 3D images, e.g. changing shapes or colours, aligning objects or positioning parts
• G06T 7/40 - Analysis of texture
• G06T 7/62 - Analysis of geometric attributes of area, perimeter, diameter or volume

Abstract

The disclosure is directed to systems, devices, and methods for generating, stabilizing, and controlling mesoscopic spin order of electrons. The device includes a two-dimensional (2D) semiconductor monolayer configured to accommodate a 2D electron gas; and a first receptacle configured to receive a first optical beam. The first optical beam is configured to interact with the 2D electron gas at a first in-plane spatial position to generate a mesoscopic magnetic/spin state of electrons in the 2D semiconductor monolayer in absence of an external magnetic field. The method includes providing a structure comprising a 2D semiconductor monolayer configured to provide a 2D electron gas; and applying a first optical beam to interact with the 2D electron gas at a first in-plane spatial position to generate a mesoscopic magnetic/spin state of electrons in the 2D semiconductor monolayer in absence of an external magnetic field.

IPC Classes  ?

• G01R 33/20 - Arrangements or instruments for measuring magnetic variables involving magnetic resonance

Abstract

A solid electrode includes particles of an electroactive material, a solid electrolyte comprising particles of an ionic conducting compound having at least one halogen element, a conductive carbon, and a coating deposited on the particles of the electroactive material, the particles of the solid electrolyte, or a combination thereof. The coating includes a metal halide, a metal sulfide, a metal phosphide, a metal oxide, a metal selenide, or a combination of two or more thereof. A method for preparing the solid electrode includes milling a mixture of the electroactive material, the conductive carbon, and the solid electrolyte to produce the coated solid electrode material comprising the coating derived from decomposition products of the ionic conducting compound, the coating deposited on the particles of the electroactive material, the solid electrolyte, or a combination thereof.

IPC Classes  ?

• H01M 4/36 - Selection of substances as active materials, active masses, active liquids
• H01M 4/136 - Electrodes based on inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFy
• H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers
• H01M 10/0562 - Solid materials

Abstract

Quantum error correction in reconfigurable atom arrays is described. A plurality of data qubits is provided, each of the plurality of data qubits disposed in a corresponding trap. A plurality of ancilla qubits is provided, each of the plurality of ancilla qubits disposed in a corresponding trap. The plurality of data qubits and the plurality of ancilla qubits are arranged in a plurality of rows and a plurality of columns, thereby forming a lattice. A plurality of permutations of the plurality of rows and the plurality of columns is performed, each of the plurality of permutations placing each of the plurality of data qubits within an interaction radius of one of the plurality of ancilla qubits, thereby forming a plurality of proximate pairs. Subsequent to each of the plurality of permutations, a global control pulse is applied to the lattice, thereby applying a gate to each of the plurality of proximate pairs, and thereby encoding a parity check matrix between the plurality of ancilla qubits and the plurality of data qubits.

IPC Classes  ?

• G06F 11/00 - Error detectionError correctionMonitoring
• G06N 10/00 - Quantum computing, i.e. information processing based on quantum-mechanical phenomena

Abstract

Constant-overhead fault-tolerant quantum computation is provided. A first plurality of physical qubits is configured to encode a first plurality of logical qubits using a quantum low-density parity-check (qLDPC) code. A second plurality of physical qubits is configured to encode a second plurality of logical qubits using an error-correcting code; and a plurality of ancilla qubits. The quantum computing system is configured to teleport at least one of the first plurality of logical qubits into a corresponding at least one of the second plurality of logical qubits via the plurality of ancilla qubits. The quantum computing system is configured to perform at least one logical operation on the at least one of the second plurality of logical qubits. The quantum computing system is configured to teleport the at least one of the second plurality of logical qubits into the at least one of the first plurality of qubits via the plurality of ancilla qubits.

IPC Classes  ?

• G06N 10/70 - Quantum error correction, detection or prevention, e.g. surface codes or magic state distillation
• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control
• G06N 10/20 - Models of quantum computing, e.g. quantum circuits or universal quantum computers
• G06N 7/01 - Probabilistic graphical models, e.g. probabilistic networks

Abstract

Embodiments of the invention are directed to methods of determining the prognosis of a breast cancer patient by evaluating the activity of the glucocorticoid receptor in tumor cells. Other embodiment include methods of treating breast cancer cells, particularly, chemo-resistant cells, with a glucocorticoid receptor antagonist and an anticancer agent or compound.

IPC Classes  ?

• A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• A61J 1/00 - Containers specially adapted for medical or pharmaceutical purposes
• A61K 31/282 - Platinum compounds
• A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
• A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
• A61K 31/567 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• A61K 33/243 - PlatinumCompounds thereof
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61N 5/00 - Radiation therapy

Abstract

The current disclosure relates to methods, compositions and kits for detecting modified adenosine in a target RNA molecule. Aspects relate to a method for detecting modified adenosine in a target ribonucleic acid (RNA) comprising contacting the target RNA with an adenosine deaminase enzyme (adenosine deaminase, RNA-specific) to generate a target RNA with deaminated adenosines and sequencing the target RNA with deaminated adenosines; wherein the modified adenosine is detected when the nucleotide sequence includes adenosine within a m6A motif.

IPC Classes  ?

• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• A61K 35/76 - VirusesSubviral particlesBacteriophages

Abstract

TT states to generate one or more distilled magic states; b) measure out a plurality of syndromes from the distillation; c) calculate one or more error rates from the plurality of syndromes; d) estimate infidelity for the distillery based upon the one or more error rates; and e) determine if the infidelity exceeds a threshold, recalibrate the distillery.

IPC Classes  ?

• G06N 10/70 - Quantum error correction, detection or prevention, e.g. surface codes or magic state distillation
• G06F 11/07 - Responding to the occurrence of a fault, e.g. fault tolerance
• G06N 10/00 - Quantum computing, i.e. information processing based on quantum-mechanical phenomena
• G01R 31/3177 - Testing of logic operation, e.g. by logic analysers
• G06N 10/20 - Models of quantum computing, e.g. quantum circuits or universal quantum computers
• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control
• G06F 30/33 - Design verification, e.g. functional simulation or model checking
• H03M 13/00 - Coding, decoding or code conversion, for error detection or error correctionCoding theory basic assumptionsCoding boundsError probability evaluation methodsChannel modelsSimulation or testing of codes

Goods & Services

Providing information in the field of economics (terms considered too vague by the International Bureau - Rule 13 (2) (b) of the Regulations). Educational services, namely, conducting classes in the field of economics at the university undergraduate and graduate level and providing publications, namely, educational materials in connection therewith; educational services, namely, conducting classes in the field of economics at the university undergraduate and graduate level and providing course materials in connection therewith; providing educational course materials for high school classes in the field of economics; providing training in the field of economics and distribution of educational materials in connection therewith for high school teachers.

Abstract

An agent associated with an electric vehicle (EV) includes a network interface configured to facilitate data communication via a network, a memory, and a processing circuit comprising a processor. The processing circuit is configured to receive pricing information for a charging interval from a charging management system, receive, via a user interface, information indicative of a charging urgency from a user, and determine an urgency value k based on the information indicative of the charging urgency, determine a desired charging rate PD for the EV, determine, based on the desired charging rate PD, a bid power Pbid for a charging interval, determine, based on the pricing information and the urgency value k, an agent monetary value for power during the charging interval, and transmit a bid including: a charge interval start and stop time, the agent monetary value, and the desired charging rate PD to the charging management system.

IPC Classes  ?

• G06Q 50/06 - Energy or water supply
• B60L 53/62 - Monitoring or controlling charging stations in response to charging parameters, e.g. current, voltage or electrical charge
• B60L 53/66 - Data transfer between charging stations and vehicles
• G06Q 10/0631 - Resource planning, allocation, distributing or scheduling for enterprises or organisations
• G06Q 20/14 - Payment architectures specially adapted for billing systems
• G06Q 30/0234 - Rebates after completed purchase
• G06Q 30/08 - Auctions
• G06Q 40/04 - Trading Exchange, e.g. stocks, commodities, derivatives or currency exchange
• H02J 7/00 - Circuit arrangements for charging or depolarising batteries or for supplying loads from batteries

Abstract

Provided are battery binder compositions. In embodiments, a battery binder composition comprises cellulose in the form of nanocellulose or microcellulose, the cellulose comprising electrode binding groups and solvent dispersing groups; and a non-aqueous solvent system. Battery electrodes and batteries comprising the battery binder compositions are also provided.

IPC Classes  ?

• H01M 50/429 - Natural polymers
• H01M 10/052 - Li-accumulators

Abstract

Aspects of the disclosure relate to nucleic acid compositions involving small nucleolar RNAs (snoRNAs), including for increasing secretion of a protein of interest. Aspects also relate to methods of using the nucleic acid compositions.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/09 - Recombinant DNA-technology
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• A61K 31/7052 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides

Abstract

A method for coating of lithium ion electrode materials via atomic layer deposition. The coated materials may be integrated in part as a dopant in the electrode itself via heat treatment forming a doped lithium electrode.

IPC Classes  ?

• H01M 4/04 - Processes of manufacture in general
• C23C 16/455 - Chemical coating by decomposition of gaseous compounds, without leaving reaction products of surface material in the coating, i.e. chemical vapour deposition [CVD] processes characterised by the method of coating characterised by the method used for introducing gases into the reaction chamber or for modifying gas flows in the reaction chamber
• H01M 4/02 - Electrodes composed of, or comprising, active material
• H01M 4/36 - Selection of substances as active materials, active masses, active liquids
• H01M 4/48 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides
• H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries

Abstract

Described herein are novel γ- and δ-propargyl carboxylic acids and esters. The novel compositions are antagonists of CSE and may be used to modulate of the activity of the carotid body, therefore providing therapeutic benefits for sleep-related breathing disorders and related conditions.

IPC Classes  ?

• A61K 31/4164 - 1,3-Diazoles
• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/216 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
• A61K 31/221 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
• A61K 31/275 - NitrilesIsonitriles
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 11/00 - Drugs for disorders of the respiratory system
• C07C 229/30 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and unsaturated
• C07C 255/07 - Mononitriles
• C07D 277/30 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07D 333/24 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Abstract

The present disclosure is generally directed to nanoparticle-containing media exhibiting enhanced optical transparency, related nanoparticles, and associated systems and methods. In certain embodiments, the refractive index (RI) of a nanoparticle comprising thermochromic material (such as VO2) can be made closer to the refractive index of a surrounding medium by tethering a material (such as a gradient copolymer) to the core region of the nanoparticle to modify the refractive index of the nanoparticle. Modifying the refractive index of the nanoparticle to be closer to the refractive index of the medium that contains the nanoparticle can render the nanoparticle-containing medium (also referred, to herein as a composite) more transparent to various wavelengths of electromagnetic radiation while imparting thermochromic properties to the nanoparticle-containing medium.

IPC Classes  ?

• C09D 5/26 - Thermosensitive paints
• C09C 3/00 - Treatment in general of inorganic materials, other than fibrous fillers, to enhance their pigmenting or filling properties
• C09C 3/06 - Treatment with inorganic compounds
• C09C 3/10 - Treatment with macromolecular organic compounds
• C09D 5/29 - Coating compositions, e.g. paints, varnishes or lacquers, characterised by their physical nature or the effects producedFilling pastes for multicolour effects
• C09D 7/40 - Additives
• C09D 7/62 - Additives non-macromolecular inorganic modified by treatment with other compounds
• C09K 9/00 - Tenebrescent materials, i.e. materials for which the range of wavelengths for energy absorption is changed as a result of excitation by some form of energy

Abstract

The present disclosure provides novel training systems and methods for recurrent neural network models. One such method comprises obtaining a first sequence of sparse input data as training data; augmenting the first sequence of sparse input data by zero-filling missing input points; training the recurrent neural network model using the augmented sequence of sparse input data to obtain a trained recurrent neural network model, and applying new data as an input to the trained recurrent neural network model, wherein the new data comprises a second sequence of sparse input data to obtain a corresponding output data sequence.

IPC Classes  ?

• G06V 10/774 - Generating sets of training patternsBootstrap methods, e.g. bagging or boosting
• G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks

Abstract

The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. The invention provides methods and compositions for stimulating an immune response against the bacteria. In certain embodiments, the methods and compositions involve a non-toxigenic Protein A (SpA) variant.

IPC Classes  ?

• C07K 14/31 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/085 - Staphylococcus
• C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria

Abstract

The present disclosure relates to a biomaterial matrix having a live bacteria impregnated hydrogel, using the biomaterial matrix to treat epidermal inflammation of an animal, and wearable electronic devices having the biomaterial matrix installed thereon.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 17/00 - Drugs for dermatological disorders
• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution
• A61L 26/00 - Chemical aspects of, or use of materials for, liquid bandages
• A61P 31/04 - Antibacterial agents

Abstract

A method of producing ethanol by electrocatalytic reduction of carbon dioxide, comprises reducing carbon dioxide in an aqueous electrolyte on an electrocatalyst with electricity. The electrocatalyst is exposed to a magnetic field of at least 400 Gauss, the electrocatalyst comprises at least one paramagnetic material, and an amount of ethanol produced by the reducing is greater than an amount of ethanol produced without the magnetic field. Also described is a system for electrocatalytic reduction of carbon dioxide, which comprises (a) and electrocatalyst, containing (i) copper and (ii) copper oxide, C60 and/or neodymium; (b) an aqueous electrolyte, in contact with the electrocatalyst; (c) a counter electrode, in ion-conductive contact with the electrocatalyst; (d) a magnet, for providing a magnetic field of at least 400 Gauss to the electrocatalyst; and (e) a power source, electronically connected to the electrocatalyst and the counter electrode.

IPC Classes  ?

• C25B 15/00 - Operating or servicing cells
• C25B 3/07 - Oxygen containing compounds
• C25B 3/26 - Reduction of carbon dioxide
• C25B 9/15 - Flow-through cells
• C25B 9/60 - Constructional parts of cells
• C25B 11/091 - Electrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of at least one catalytic element and at least one catalytic compoundElectrodes formed of electrocatalysts on a substrate or carrier characterised by the electrocatalysts material consisting of two or more catalytic elements or catalytic compounds

Abstract

Provided herein are compositions and methods for stimulating T-cell-based anti-tumor immunity by administration of trans-vaccenic acid (TVA), an active derivative thereof, or an inhibitor of GPR43 expression or activity. In particular embodiments, TVA, a TVA derivative, or an inhibitor of GPR43 expression or activity is administered to boost an endogenous T-cell response and/or is co-administered with a T-cell-based therapy, such as immune checkpoint blockade therapies, CAR-T therapies, monoclonal antibody therapies, bispecific T-cell engagers therapies, etc.

IPC Classes  ?

• A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/202 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having three or more double bonds, e.g. linolenic acid
• A61K 31/397 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• A61K 40/31 - Chimeric antigen receptors [CAR]
• A61K 40/33 - AntibodiesT-cell engagers
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The current disclosure provides for methods for diagnosing, prognosing, and treating cerebral cavernous malformations (CCMs). Also provided are methods for determining the efficacy of therapeutic treatments for CCM, such as those that may be in a clinical trial setting or administered by a health care professional. Accordingly, aspects of the disclosure relate to method for treating cerebral cavernous malformations (CCMs) in a subject, the method comprising administering a therapy to a subject determined to have differential expression of one or more biomarkers selected from the biomarkers listed in Tables S1-S8 and S13 in a biological sample from the subject. Further aspects relate to A method for treating cerebral cavernous malformations (CCMs) in a subject, the method comprising administering a therapy to a subject determined to have differential expression of one or more biomarkers selected from let-7e-5p, miR-93-5p, miR-20b-5p, miR-128-3p, miR-9-5p, IL-10, Tsp-2, IL-2, and TNER1.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The invention provides method for igniting pressurized fuel, the method comprising placing fuel into a combustion chamber; mixing the fuel with supercritical carbon dioxide and oxidizer to create a mixture; and contacting the fuel-air mixture with a laser, whereby the laser is pointed to a first point within the chamber. Also provided is a laser ignitor for carbon dioxide combustors, the ignitor comprising: an elongated housing capable of varying in length, the housing having a first proximal end and a second distal end; a laser head in close spatial relationship to the proximal end, wherein the laser head generates a first laser beam; a seal at the distal end that is optically transparent to the laser beam and physically opaque to combustion contaminants; an algorithm for directing the first beam to a first point within a combustion chamber for a first period of time; and an algorithm for directing a second laser beam to a second point within the combustion chamber for a second period of time.

IPC Classes  ?

• F02C 7/264 - Ignition
• F23Q 13/00 - Ignition not otherwise provided for

Abstract

A molecular-spin qubit includes a molecular color center having a ground state and an excited state. The ground state has non-zero spin with at least first and second sublevels. The molecular-spin qubit also includes a host matrix that is non-isostructural with the molecular color center. The molecular color center is diluted in the host matrix. An optical transition between the ground and excited states lies in the optical region of the electromagnetic spectrum. A spin transition between the first and second sublevels lies in the microwave or millimeter-wave regions of the electromagnetic spectrum. Each of the first and second sublevels is first-order insensitive to magnetic fields near zero magnetic. The molecular color center and host matrix may each be formed from strong-field ligands bound to a metal-atom center. One example of the molecular-spin qubit is Cr(IV)(o-toyl)4 diluted in a host matrix of Sn(IV)(4-fluoro-2-methylphenyl)4.

IPC Classes  ?

• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control

Abstract

Stretchable light-emitting polymers are provided. Stretchable organic light-emitting diodes including the stretchable light-emitting polymers are further provided.

IPC Classes  ?

• H10K 50/11 - OLEDs or polymer light-emitting diodes [PLED] characterised by the electroluminescent [EL] layers
• C08F 26/06 - Homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a heterocyclic ring containing nitrogen
• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• H10K 50/15 - Hole transporting layers
• H10K 50/17 - Carrier injection layers
• H10K 85/10 - Organic polymers or oligomers
• H10K 102/00 - Constructional details relating to the organic devices covered by this subclass

Abstract

An optical cavity includes a plurality of mirrors that reflect light along a closed path. First and second mirrors of the plurality of mirrors define an optical axis therebetween. The optical cavity includes first and second lenses located between the first and second mirrors along the optical axis. A mode of the optical cavity has a waist located between the first and second intracavity lenses. Small values of the waist (e.g., <10 microns) produce large cooperativities that relax requirements for the cavity finesse (i.e., reflectivity of the mirrors). The mirrors may be retroreflecting to create a Fabry-Perot cavity. Alternatively, the first and second mirrors may define one segment of a ring cavity. The optical cavity may be used to trap, read, entangle, and drive nonlinear emitters (e.g., atoms, color centers, quantum dots) located near the waist.

IPC Classes  ?

• G21K 1/00 - Arrangements for handling particles or ionising radiation, e.g. focusing or moderating
• G02B 17/00 - Systems with reflecting surfaces, with or without refracting elements
• G02B 26/00 - Optical devices or arrangements for the control of light using movable or deformable optical elements

Abstract

Provided herein are pharmaceutical compositions and dietary supplements comprising vanadyl sulfate (VS) and method of use thereof for the induction of cell death in senescent cells. In particular. VS compositions find use in clearance of age-related and/or therapy-induced senescent cells and reduction/elimination of senescence associated secretory phenotype (SASP)-induced inflammatory environments in subjects. and therefore in the treatment/prevention of age-related conditions and/or cancer.

IPC Classes  ?

• A61K 33/24 - Heavy metalsCompounds thereof
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

Described herein are polymersomes (PSs) as a delivery platform that display enhanced macromolecular encapsulation efficiency with facile, streamlined processing. The formulations herein demonstrate rapid assembly of near-monodisperse PSs without organic solvents to circumvent purification issues. This is achieved through two design principles: 1) temperature responsive PS assembly and 2) affinity-driven payload encapsulation. The BCPs are solubilized in aqueous buffer when refrigerated (4 °C) but self-assemble at room temperature (20 °C) into homogeneous PSs. This is achieved by incorporating polymers segments with a lower critical solution temperature (LCST) below room temperature but above the freezing point of water. BCPs are dissolved alongside a hydrophilic payload, and their uniform self-assembly bypasses solvent and size-exclusion purifications.

IPC Classes  ?

• C08G 81/00 - Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers
• C08L 33/06 - Homopolymers or copolymers of esters of esters containing only carbon, hydrogen, and oxygen, the oxygen atom being present only as part of the carboxyl radical
• C08J 3/075 - Macromolecular gels
• A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol

Abstract

Systems and methods for delivering a drug to a patient's kidney. The present systems comprise a urethral catheter and a ureteral catheter sized to fit through the urethral catheter. The urethral catheter includes a balloon configured to be inflated in the patient's bladder to retain the urethral catheter in the patient's urethra. The ureteral catheter includes a balloon configured to be inflated in the patient's ureter and/or kidney while a distal end of the ureteral catheter is disposed in the patient's kidney. The ureteral catheter balloon can help retain liquid in the kidney to enable expanded contact areas with kidney tissues and extended dwell times (e.g., periods of exposure) of the drug in the kidney. The balloons also help retain the catheters in the patient's urinary tract, such that the catheter system can be used to deliver a drug to the patient's intermittently or periodically over a period of days or weeks.

IPC Classes  ?

• A61M 25/10 - Balloon catheters
• A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
• A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems

Abstract

xx centers, than diamond layers fabricated without the step of hydrogen degassing.

IPC Classes  ?

• C01B 32/25 - Diamond
• C30B 29/04 - Diamond
• B01J 3/06 - Processes using ultra-high pressure, e.g. for the formation of diamondsApparatus therefor, e.g. moulds or dies
• C30B 29/02 - Elements

Abstract

The present disclosure includes an arm support for supporting a patient's arm during a procedure, such as a cardiac catheterization procedure. Some arm supports include a unitary body defining: a lower portion, an upper portion, a first end, a second end, a proximal side, and a distal side of the arm support, where the lower portion of the unitary body defines a mount configured to be coupled to a patient support, and where the upper portion of the unitary body defines a support surface extending between the first and second ends, where the support surface is shaped to support a patient's arm.

IPC Classes  ?

• A61M 5/52 - Arm-rests
• A61M 25/01 - Introducing, guiding, advancing, emplacing or holding catheters

Abstract

Disclosed are compositions and methods useful for cancer treatment. The composition and methods include overexpressing BAMBI in a population of immune cells, such as myeloid-derived suppressor cells, in order to improve the immune cells immunogenic and/or anti-tumor effects. Also disclosed are compositions and methods for determining responsiveness to a radiotherapy and/or immunotherapy.

IPC Classes  ?

• A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 5/078 - Cells from blood or from the immune system